Compare ServiceNow Inc (NOW) vs Summit Therapeutics Inc (SMMT) Price & Performance

ServiceNow (NOW) trades at $139.75, up 1.36% with strong technical momentum and bullish moving average signals. The company demonstrates robust fundamentals with $13.28B revenue in 2025, 74.77% gross margins, and consistent earnings beats. Recent AI product growth exceeding $1B annual contract value and positive market sentiment position the stock for potential upside toward the $146.04 consensus target.

Outlook remains positive with AI-driven growth catalysts, though premium valuation (P/E 87.34) and competitive pressures present risks. Wall Street maintains strong buy sentiment (87% buy ratings) with institutional confidence in the company's enterprise software leadership and AI integration strategy supporting long-term growth potential.

Summit Therapeutics (SMMT) trades at $17.59, down 2.01% on the day, amid mixed earnings performance but strong analyst support with a consensus price target of $29.33. The stock shows a bullish technical signal from moving averages, with key support at $17 and resistance at $18. Recent news highlights a major $2 billion strategic investment from AstraZeneca and expanded clinical collaborations, boosting investor optimism despite current negative profitability metrics.

The outlook for SMMT is heavily driven by clinical progress and partnerships, offering significant upside if drug trials succeed, but carries high risk due to substantial losses, negative cash flow from operations, and reliance on positive trial outcomes. Investors should weigh the potential rewards against the company's current financial health and execution risks.